Results 251 to 260 of about 137,029 (384)

Adjustment of Surveillance Intervals for Ulcerative Colitis‐Associated Neoplasia Based on Disease Duration

Digestive Endoscopy, EarlyView.
ABSTRACT Objectives The risk of colitis‐associated cancer increases with disease duration in ulcerative colitis (UC), yet surveillance colonoscopy protocols generally stratify risk uniformly for patients with disease lasting over 8 years. This study evaluated whether shorter surveillance intervals might enhance lesion detection rates in patients with ...
Ryoya Sakakibara, Shinya Sugimoto, Yuta Kaieda, Hiroki Kiyohara, Yusuke Yoshimatsu, Kaoru Takabayashi, Soichiro Murakami, Miho Kawaida, Tomohisa Sujino, Naoki Hosoe, Motohiko Kato, Yasushi Iwao, Yohei Mikami, Takanori Kanai   +13 more
wiley   +1 more source

Optimizing Infliximab Use in Real-World Inflammatory Bowel Disease: Insights from a Population Pharmacokinetic Model Integrating Intravenous and Subcutaneous Formulations. [PDF]

Gut Liver
Jung SH, Kang SB.
europepmc   +1 more source

FRI0052 To evaluate antibodies antinuclear (ana) in rheumatoid arthritis with infliximab treatmentoid [PDF]

, 2001
Florian Ruiz, G. Bonilla, Gisela Diaz, JM Gonzalez-Tarrio, R Alvarez-Doforno, Alejandro Balsa, E. Martín‐Mola   +6 more
openalex   +1 more source

Predicting resistance to biological therapy using human leukocyte antigen genes in patients with inflammatory bowel disease. [PDF]

Therap Adv Gastroenterol
Domingues Â, Carvalho A, Martinho A, Soares C, Martins D, Sousa P, Araújo R, Cancela E, Silva A, Ministro P.   +9 more
europepmc   +1 more source

Use of Infliximab in the Treatment of Crohnʼs Disease in Children and Adolescents

, 2001
Jeffrey S. Hyams
openalex   +1 more source

Immune checkpoint inhibitor‐induced pancreatic enzyme elevation in melanoma patients: Incidence, management and therapy—A multicentre analysis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Background, key points, current state of management in dermato‐oncology centres and algorithm for standardized monitoring and management of ICIPI; *routine radiographic imaging according to respective guidelines; **3 months after routine radiographic staging (6‐monthly); ***if not recently performed as part of the routine staging.
M. Brandlmaier, M. Hoellwerth, T. Silly, C. Hoeller, L. Koch, E. Richtig, K. Binder, B. Lange‐Asschenfeldt, M. Barta, M. Schmid‐Simbeck, F. Froehlich, R. Dummer, L. Muigg, W. Hitzl, P. Koelblinger   +14 more
wiley   +1 more source

Understanding and addressing anti-drug antibody formation in tumor necrosis factor-α inhibitor therapy for ankylosing spondylitis. [PDF]

J Rheum Dis
Kim TJ.
europepmc   +1 more source

FRI0070 Safety and tolerability of a rapid infusion of remicade (infliximab) in the treatment of rheumatoid arthritis

, 2001
RA Isern, C Sanders, Gareth Hughes, S Toder, Gregory F. Keenan   +4 more
openalex   +1 more source

Evaluation of the risk of heart failure with tumour necrosis factor inhibitors: A large‐scale meta‐analysis in immune‐mediated inflammatory diseases

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Graphical abstract summarising the results of the present systematic review and meta‐analysis on the effect of tumour necrosis factor inhibitors on the risk of heart failure in immune‐mediated inflammatory diseases. CI, confidence interval; IMID, immune‐mediated inflammatory diseases; RCT, randomised controlled trial; RR, risk ratio; TNF, tumour ...
Noémi Ágnes Galajda, Fanni Adél Meznerics, Péter Mátrai, Alíz Fazekas, Anna Sára Lengyel, Mária Veronika Kolonics, Lajos Vince Kemény, Dezső Csupor, Péter Hegyi, Péter Holló, András Bánvölgyi   +10 more
wiley   +1 more source

Abdominal tuberculosis in a patient with ankylosing spondylitis and infliximab: is the risk still too great? A case report. [PDF]

J Surg Case Rep
Moyón MÁ, Añazco JS, Vásconez AE, Larreategui D, Torres MB, Moyón N, Borja T, Molina GA.   +7 more
europepmc   +1 more source